The National Institute for Health and Care Excellence (NICE) has recommended teplizumab, marketed under the brand name Tzield by Sanofi, for use on the National Health Service, making England the first country in Europe to approve a disease-modifying therapy capable of delaying the onset of type 1 diabetes. The landmark decision, published on June 23, 2026, marks a historic shift in how the autoimmune condition is managed, moving from reactive treatment to proactive intervention before clinical symptoms appear.
Teplizumab is approved for adults and children aged eight years and older who have been diagnosed with stage 2 type 1 diabetes. At this stage, the autoimmune process that destroys insulin-producing beta cells in the pancreas has already begun, but patients have not yet developed the clinical symptoms associated with the disease, such as excessive thirst, frequent urination, and unexplained weight loss. The treatment is administered intravenously as a single course over 14 consecutive days.
The approval is based on findings from the TN-10 clinical trial, which enrolled 76 participants with stage 2 type 1 diabetes who also had a family history of the condition. Results demonstrated that teplizumab delayed the onset of clinical type 1 diabetes symptoms by approximately 32 months, nearly three years, compared to a placebo group. This delay provides patients and their families with additional years free from the burden of daily insulin injections, blood sugar monitoring, and the associated risks of hypoglycaemia.
NICE estimates that approximately 1,100 people will be eligible for the treatment in the first year, with that number stabilising to around 820 patients annually from the third year onwards. The therapy will be made available to NHS England patients within 90 days of the final guidance publication. Patients in NHS Wales will gain access within 60 days from the June 23 announcement, providing a slightly faster timeline for Welsh residents.
Health professionals and patient advocacy groups have welcomed the decision as a transformative moment in diabetes care. Type 1 diabetes affects around 400,000 people in the United Kingdom and requires lifelong management with insulin therapy. By intervening at the pre-symptomatic stage, teplizumab offers the possibility of preserving residual beta cell function for longer, which research suggests can lead to better long-term health outcomes and reduced complications.
The approval also raises important questions about screening and early detection. For teplizumab to reach eligible patients, healthcare systems will need robust screening programmes to identify individuals at stage 2, particularly among first-degree relatives of people with type 1 diabetes. Experts have noted that expanding screening capabilities will be essential to realising the full potential of this therapy and ensuring equitable access across the country.
Looking ahead, researchers and clinicians are optimistic that the approval of teplizumab could pave the way for additional disease-modifying treatments in the pipeline. Several other immunomodulatory therapies are currently under investigation, and the precedent set by NICE could accelerate their evaluation across Europe. For now, the focus remains on implementing the rollout effectively and ensuring that eligible patients are identified and offered this groundbreaking treatment as swiftly as possible.
Comments